Article
Cell Biology
Raghavan Chinnadurai, Amanda Paige Porter, Mihir Patel, Ariel Joy Lipat, Mathews H. Forsberg, Devi Rajan, Peiman Hematti, Christian M. Capitini, Charles Bruker
Summary: B7 family proteins and tryptophan degrading enzymes play crucial roles in tumor immune evasion. The interactions between tumor cells, stromal cells, and immune cells contribute to the development of an immunosuppressive tumor microenvironment. IFN-γ activated MSCs exhibit superior protection of HepG2 cells from PBMC mediated lysis and blockade of IFN-γ driven IDO activity in MSCs could be a potential immunotherapeutic strategy for hepatocellular carcinoma regression.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Physiology
Corina Bello, Paul Philipp Heinisch, Maks Mihalj, Thierry Carrel, Markus M. Luedi
Summary: IDO is a rate-limiting enzyme in the tryptophan catabolism pathway, playing a crucial role in immune modulation and the pathogenesis of various diseases. Its involvement has been extensively studied in autoimmune processes and highly malignant cancers, with potential as a predictive biomarker and therapeutic target in immune-mediated diseases. Additionally, IDO shows promise as a biomarker in the pre-operative setting for decision-making and treatment of surgical patients experiencing trauma-induced stress.
FRONTIERS IN PHYSIOLOGY
(2021)
Article
Immunology
Ru Meng, Yong Fu, Yaogang Zhang, Yalin Mou, Gongguan Liu, Haining Fan
Summary: This study demonstrates the essential role of IDO1 signaling in inducing immunosuppression in mice infected with Echinococcus multilocularis, by preventing the maturation and migration potential of dendritic cells and leading to immune tolerance of T cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Nirmalya Pradhan, Nasim Akhtar, Barnali Nath, Jorge Pena-Garcia, Anjali Gupta, Horacio Perez-Sanchez, Sachin Kumar, Debasis Manna
Summary: Quinine derivatives effectively inhibit the activity of IDO1 by competing with heme, providing a potential avenue for immunotherapy-based drug discovery strategies.
CHEMICAL COMMUNICATIONS
(2021)
Review
Oncology
Yu Yao, Heng Liang, Xin Fang, Shengnan Zhang, Zikang Xing, Lei Shi, Chunxiang Kuang, Barbara Seliger, Qing Yang
Summary: IDO1, a heme-containing enzyme, plays a crucial role in the kynurenine pathway of tryptophan metabolism, with implications in immunity and neuronal function. Despite potential applications in cancer and neurodegenerative diseases, cautionary notes from clinical trials indicate a need for better understanding of IDO1 inhibition mechanisms.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Immunology
Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman, Guido J. R. Zaman
Summary: NTRC 3883-0 is a novel small molecule IDO1 inhibitor that showed immunomodulatory activity by releasing the inhibitory effect of IDO1 on CD8-positive T cell proliferation. It effectively counteracted the IDO1-induced modulation of L-tryptophan and L-kynurenine levels in a syngeneic mouse model using IDO1-overexpressing B16F10 melanoma cells. The expression and activity of IDO1 in primary cell cultures from ovarian cancer patients' malignant ascites could be inhibited by NTRC 3883-0, suggesting its potential for patient stratification.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Binbin Pan, Feng Zhang, Jian Sun, Dawei Chen, Wenjuan Huang, Hao Zhang, Changchun Cao, Xin Wan
Summary: The study suggests that IDO may serve as a promising biomarker for predicting CKD and assessing kidney function. Even after adjusting for CKD-related indices, IDO remains an independent risk factor for ACR.
JOURNAL OF IMMUNOLOGY RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Leila Sawada, Antonio Carlos Rosario Vallinoto, Igor Brasil-Costa
Summary: EBV is an oncovirus associated with various types of cancer, with the reason for cancer development in only some infected individuals still unknown. EBV-associated cancers are more aggressive and resistant to treatment compared to EBV-negative cancers, making monoclonal antibodies targeting immune checkpoints a potential therapy.
Article
Biochemistry & Molecular Biology
Ilona Sadok, Kamila Rachwal, Ilona Jonik, Magdalena Staniszewska
Summary: A new HPLC-DAD method for determining IDO1 activity in human cancer cells has been developed and successfully validated, demonstrating its applicability in different cancer cell types. This approach provides a useful model for studying the role of the kynurenine pathway in cancer biology.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
(2021)
Review
Chemistry, Medicinal
Rahul Singh, Deepak B. Salunke
Summary: IDO1 enzyme catalyzes the initial step of kynurenine pathway and is implicated in immune modulation, antioxidation, and cancer progression. Overexpression of IDO1 plays a pivotal role in immune evasion and cancer development. Research and development of IDO1 inhibitors holds significant potential in immunotherapy and disease treatment.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Immunology
Sameh Souissi, Randa Ghedira, Yosra Macherki, Ahlem Ben-Haj-Ayed, Sallouha Gabbouj, Yasmine Remadi, Imen Sfar, Zohra Chadli, Karim Aouam, Mohsen Hassine, Noureddine Bouaouina, Abdelfattah Zakhama, Elham Hassen
Summary: This study found that IDO1 mRNA expression was significantly upregulated and IDO2 mRNA expression was significantly downregulated in peripheral blood of NPC patients. Additionally, plasma Kyn levels and Kyn/Trp ratio were significantly higher in patients compared to controls. The plasma Kyn/Trp ratio at diagnosis was associated with cancer stage and predicted survival outcome.
IMMUNITY INFLAMMATION AND DISEASE
(2022)
Review
Pharmacology & Pharmacy
Ana Dolsak, Stanislav Gobec, Matej Sova
Summary: This review discusses the key step of tryptophan metabolism and the importance of relevant enzymes in pathological conditions. In recent years, many inhibitors targeting these enzymes have been developed, and these inhibitors have entered clinical trials.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Engineering, Biomedical
Yixuan Guo, Yu Liu, Wei Wu, Daishun Ling, Qiao Zhang, Peng Zhao, Xi Hu
Summary: This article will discuss different types of IDO inhibitors and relevant clinical trials, especially feasible combined therapeutic modalities. In addition, it will also review cutting-edge nanomedicines that combine IDO inhibitors with other therapeutic modalities to effectively enhance the effectiveness of cancer therapy. Finally, the prospects of IDO inhibitors in clinical application and potential breakthroughs will be briefly discussed.
Article
Biochemistry & Molecular Biology
Theodoros Eleftheriadis, Georgios Pissas, Georgios Filippidis, Vassilios Liakopoulos, Ioannis Stefanidis
Summary: The study showed that IDO plays a crucial role in cellular senescence during anoxia and reoxygenation, affecting the GCN2K and AhR pathways. Cellular senescence influences the outcome of AKI, highlighting the importance of investigating the role of IDO in cellular senescence and the potential therapeutic effects of IDO inhibitors.
Article
Developmental Biology
Gayathri Guru Murthy, Mallory A. Prideaux, Madison Armstrong, H. Mark Kenney, Sarah E. Latchney, Martha Susiarjo, Shawn P. Murphy
Summary: Research has shown that IDO1 expression is activated in the human placenta between the 13th and 14th weeks of pregnancy, increases through the 2nd trimester, and remains elevated at term. Basal IDO1 expression is restricted to placental endothelial cells, and different types of interferons have distinct effects on its expression in the placenta.
